BAM Logo

Special Haemostasis

EPTIS factsheet 580335 | Last revision 2019-05-20 | URL: https://www.eptis.bam.de/pts580335 https://www.eptis.bam.de/pts580335

PT provider
Based in Australia
Language(s) English
Product groups Human test material
Testing fields Medical analysis
Technical details
Test item Tested property Testing method
Plasma (lyophilised) Lupus Anticoagulant -
Protein C, Protein S, Antithrombin and APC resistance -
Von Willebrand Factor -
FVIII Inhibitor -
Tube with dried agonist PFA-100/200 analysis -
Plasma (lyophilised) Unfractionated Heparin Monitoring -
Low Molecular Weight Heparin Monitoring -
Dabigatran (Thrombin Inhibitor) -
Apixaban (Anti Xa) -
Rivaroxaban (Anti Xa) -
Factor XIII (Screen and Assay) -
Aims of the PT scheme
Target group of participants
Linked to specific legislation / standards
Additional, subsidiary aims
Number of participants
Accredited or otherwise reviewed by a 3rd party

Accredited by NATA on the basis of Accredited by NATA on the basis of Accredited by NATA on the basis of ISO/IEC 17043: 2010

Operation is commissioned / requested by
Fees and frequency
Participation fee Yes
Regularly operated Yes (Lupus Anticoagulant: 2 samples per survey/3 surveys, Other options: 2 samples per survey/2 surveys)
Year of first operation
Contact details of the PT provider
Provider Contact person
Suite 201/8 Herbert Street
St Leonards, 2065

Phone: (61 2) 9045 6000
Fax: (61 2) 9356 2003
Web: https://www.rcpaqap.com.au/ https://www.rcpaqap.com.au/
Megan Cooke
Phone: (61 2) 9045 6012
Fax: (61 2) 9356 2003
Email: megan.cooke@rcpaqap.com.au megan.cooke@rcpaqap.com.au
If you find any mistakes please contact the responsible EPTIS coordinator in Australia, Ms Luminata Antin. Ms Luminata Antin.
Any questions or problems? Please contact us at eptis@bam.de.
Application version: 1.21